MetaVia Inc.
corporate_fare Company Profile
MetaVia Inc. (NASDAQ:MTVA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 37 items for MTVA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for MTVA spans 8-K, 10-Q, 424B5.
Recent high-impact activity:
- MetaVia Hit With Nasdaq Deficiency Notice After Equity Falls Below $2.5M
- MetaVia's DA-1726 Matches Retatrutide Weight Loss With Less Appetite Suppression in Preclinical Study
- MetaVia 10-Q: $8.8M Cash Into 1Q 2027, $13.8M Nine-Month Loss, Going Concern Stands
- MetaVia Q3: $8.8M Cash Into 1Q 2027, Net Loss $4.6M, Phase 2 MetALD Set for 2H 2027
- DA-1726 Cuts Liver Fat 68.1% Placebo-Adjusted in Interim Phase 1 Data
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 56,090 shares in MTVA as of the October 30, 2026 settlement, a 43.2% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 21.5% of MTVA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for MTVA, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.
ATM Program Expanded · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →